Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Somer S;Somer S; Levy AP; Levy AP
  • Source:
    International journal of molecular sciences [Int J Mol Sci] 2020 Dec 30; Vol. 22 (1). Date of Electronic Publication: 2020 Dec 30.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
    • Abstract:
      Atherosclerotic cardiovascular disease (CVD) is the major cause of morbidity and mortality in individuals with diabetes mellitus (DM). Preclinical models have suggested that excessive oxidative stress and hyperglycemia are directly responsible for this pathological association. However, numerous clinical trials involving the administration of high doses of the antioxidant vitamin E or attempts at strict glycemic control have failed to show a significant reduction of CVD in DM patients. We describe here a possible explanation for the failure of these trials, that being their lack of proper patient selection. The haptoglobin (Hp) genotype is a major determinant of the risk of CVD in the setting of DM. Treatment of individuals with the high-risk Hp genotype with antioxidants or aggressive glycemic control has shown benefit in several small studies. These studies suggest a precision medicine-based approach to preventing diabetes complications. This approach would have a profound effect on the costs of diabetes care and could dramatically reduce morbidity from diabetes.
    • References:
      J Am Coll Cardiol. 2016 May 31;67(21):2553-4. (PMID: 27230052)
      N Engl J Med. 2000 Jan 20;342(3):154-60. (PMID: 10639540)
      Diabetes Res Clin Pract. 2017 Sep;131:200-207. (PMID: 28759833)
      Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):341-7. (PMID: 18032779)
      Arch Intern Med. 1998 Mar 23;158(6):668-75. (PMID: 9521232)
      JAMA. 2005 Jul 6;294(1):56-65. (PMID: 15998891)
      Gerontology. 2019;65(1):9-19. (PMID: 30179866)
      Clin Diabetes. 2016 Jul;34(3):148-57. (PMID: 27621532)
      Biochim Biophys Acta. 1986 Aug 7;860(1):84-90. (PMID: 3089279)
      Diabetes Metab Syndr Obes. 2014 May 23;7:169-83. (PMID: 24920930)
      N Engl J Med. 2008 Jun 12;358(24):2560-72. (PMID: 18539916)
      J Diabetes Res. 2018 May 20;2018:6125420. (PMID: 29888289)
      Clin Chim Acta. 2019 Jul;494:138-142. (PMID: 30898509)
      Front Cardiovasc Med. 2018 Oct 16;5:141. (PMID: 30386783)
      Korean J Intern Med. 2015 Sep;30(5):571-9. (PMID: 26354050)
      Eur J Prev Cardiol. 2018 Sep;25(14):1502-1519. (PMID: 29799294)
      Diabetes Care. 2014;37(1):9-16. (PMID: 24356592)
      J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):18-20. (PMID: 11967789)
      Transl Stroke Res. 2017 Dec;8(6):612-616. (PMID: 28386733)
      BMJ. 2020 Mar 4;368:m513. (PMID: 32132002)
      J Am Coll Cardiol. 2013 Feb 19;61(7):728-37. (PMID: 23312704)
      Pharmgenomics Pers Med. 2018 Apr 23;11:71-82. (PMID: 29731659)
      Diabetes. 2008 Oct;57(10):2794-800. (PMID: 18599520)
      Am J Epidemiol. 1990 Dec;132(6):1141-55. (PMID: 2260546)
      Am J Gastroenterol. 2008 Dec;103(12):3029-35. (PMID: 18853970)
      Circ Res. 2007 Jul 6;101(1):106-10. (PMID: 17525367)
      N Engl J Med. 2008 Jun 12;358(24):2545-59. (PMID: 18539917)
      Clin Chem. 1996 Oct;42(10):1589-600. (PMID: 8855140)
      Diabetologia. 2007 Nov;50(11):2280-8. (PMID: 17768606)
      J Am Coll Cardiol. 2020 Feb 11;75(5):522-524. (PMID: 32029135)
      World J Diabetes. 2015 Oct 10;6(13):1246-58. (PMID: 26468341)
      Diabetes Care. 2004 Nov;27(11):2767. (PMID: 15505023)
      J Am Coll Cardiol. 2020 Feb 11;75(5):512-521. (PMID: 32029134)
      Cardiovasc Diabetol. 2019 May 30;18(1):65. (PMID: 31146758)
      Ann Intern Med. 2005 Jan 4;142(1):37-46. (PMID: 15537682)
      Am J Hum Genet. 1991 Jul;49(1):158-66. (PMID: 2063867)
      Diabetes Care. 2003 Jan;26 Suppl 1:S28-32. (PMID: 12502617)
      Lancet. 2010 Jun 26;375(9733):2215-22. (PMID: 20609967)
      J Alzheimers Dis. 2020;74(2):649-658. (PMID: 32065799)
      Lancet Diabetes Endocrinol. 2018 Sep;6(9):714-724. (PMID: 29859908)
      Eur J Prev Cardiol. 2018 Sep;25(14):1498-1501. (PMID: 30103628)
      Curr Diab Rep. 2017 Jun;17(6):42. (PMID: 28451949)
      Diabetes Care. 2003 Sep;26(9):2628-31. (PMID: 12941730)
      Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):774-786. (PMID: 30727751)
      Nutr Diabetes. 2020 Apr 27;10(1):13. (PMID: 32341356)
      Diabetes Care. 2009 Jan;32(1):187-92. (PMID: 19092168)
    • Contributed Indexing:
      Keywords: cardiovascular disease; diabetes mellitus; glycemic control; haptoglobin; hemoglobin; vitamin E
    • Accession Number:
      0 (Glycated Hemoglobin A)
      0 (Haptoglobins)
      0 (Vitamins)
      1406-18-4 (Vitamin E)
    • Publication Date:
      Date Created: 20210105 Date Completed: 20210913 Latest Revision: 20210913
    • Publication Date:
      20220902
    • Accession Number:
      PMC7796233
    • Accession Number:
      10.3390/ijms22010287
    • Accession Number:
      33396615